Ontology highlight
ABSTRACT:
SUBMITTER: Sabari JK
PROVIDER: S-EPMC5388194 | biostudies-literature | 2017
REPOSITORIES: biostudies-literature
Sabari Joshua K JK Santini Fernando C FC Schram Alison M AM Bergagnini Isabella I Chen Ruqin R Mrad Chebli C Lai W Victoria WV Arbour Kathryn C KC Drilon Alexander A
OncoTargets and therapy 20170406
Brigatinib (AP26113) is a dimethylphosphine oxide group-containing tyrosine kinase inhibitor (TKI) constructed around a bisanilinopyrimidine scaffold with potent activity against the anaplastic lymphoma kinase (ALK) and several other targets. Despite the activity of first- and second-generation ALK inhibitors in advanced <i>ALK</i>-rearranged lung cancers, the development of acquired resistance represents an ongoing challenge. Later generation ALK inhibitors such as brigatinib are important pote ...[more]